文献速递肝病消化道肿瘤与早癌

肝细胞Shp2缺失抑制由致癌β-连环蛋白、PIK3CA和MET驱动的肝癌发生

Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET.
PubMed 文献 · J Hepatol · 2018-03-02

本研究通过流体动力学尾静脉注射将表达c-Met与ΔN90-β-连环蛋白(MET/CAT)或c-Met与PIK3CAH1047R(MET/PIK)的质粒导入野生型和Shp2肝细胞特异性敲除(Shp2hep-/-)小鼠,比较肝脏肿瘤负荷并探讨机制。结果显示,尽管诱导了氧化和代谢应激,肝细胞Shp2缺失仍抑制了由MET/CAT或MET/PIK过表达驱动的肝癌发生,抑制了c-Met、Wnt/β-连环蛋白、Ras/Erk和PI3K/Akt通路的增殖信号,但外源表达致癌基因后触发了细胞衰老。结论认为Shp2是这些致癌蛋白肝细胞内在致瘤信号所必需的,即使Shp2缺失诱导了促瘤肝脏微环境;作者建议通过抑制Shp2并抑制因Shp2抑制而产生的促瘤基质因子,为驱动HCC的致癌RTK等提供新的治疗策略。

要点

  • 肝细胞Shp2缺失抑制MET/CAT或MET/PIK过表达驱动的肝癌发生。
  • Shp2缺失抑制c-Met、Wnt/β-连环蛋白、Ras/Erk和PI3K/Akt增殖信号。
  • 外源表达致癌基因后Shp2缺失触发细胞衰老,但诱导促瘤肝脏微环境。

核心结论

  • Shp2作为RTK下游分子,是这些致癌蛋白肝细胞内在致瘤信号所正向需要的,即使Shp2缺失诱导了促瘤肝脏微环境。
  • 这些数据提示,通过抑制Shp2并同时抑制因Shp2抑制而产生的促瘤基质因子,可能为驱动HCC的致癌RTK及其他上游分子提供新的更有效治疗策略。

研究设计与样本

  • 将表达c-Met与ΔN90-β-连环蛋白(MET/CAT)或c-Met与PIK3CAH1047R(MET/PIK)的两对质粒通过流体动力学尾静脉注射导入野生型和Shp2hep-/-小鼠。
  • 比较肝脏肿瘤负荷,并采用多学科方法研究发病机制和分子机制。

主要发现

  • 尽管诱导了氧化和代谢应激,肝细胞Shp2缺失抑制了由MET/CAT或MET/PIK过表达驱动的肝癌发生。
  • Shp2缺失抑制了来自c-Met、Wnt/β-连环蛋白、Ras/Erk和PI3K/Akt通路的增殖信号。
  • 外源表达致癌基因后,Shp2缺失触发了细胞衰老。

临床怎么用

  • 作者认为,这些数据提示通过抑制Shp2并同时抑制因Shp2抑制而产生的促瘤基质因子,可能为驱动HCC的致癌RTK及其他上游分子提供新的更有效治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Shp2 is an SH2-tyrosine phosphatase acting downstream of receptor tyrosine kinases (RTKs). Most recent data demonstrated a liver tumor-suppressing role for Shp2, as ablating Shp2 in hepatocytes aggravated hepatocellular carcinoma (HCC) induced by chemical carcinogens or Pten loss. We further investigated the effect of Shp2 deficiency on liver tumorigenesis driven by classical oncoproteins c-Met (receptor for HGF), β-catenin and PIK3CA. METHODS: We performed hydrodynamic tail vein injection of two pairs of plasmids expressing c-Met and ΔN90-β-catenin (MET/CAT), or c-Met and PIK3CAH1047R (MET/PIK), into WT and Shp2hep-/- mice. We compared liver tumor loads and investigated the pathogenesis and molecular mechanisms involved using multidisciplinary approaches. RESULTS: Despite the induction of oxidative and metabolic stresses, Shp2 deletion in hepatocytes suppressed hepatocarcinogenesis driven by overexpression of oncoproteins MET/CAT or MET/PIK. Shp2 loss inhibited proliferative signaling from c-Met, Wnt/β-catenin, Ras/Erk and PI3K/Akt pathways, but triggered cell senescence following exogenous expression of the oncogenes. CONCLUSIONS: Shp2, acting downstream of RTKs, is positively required for hepatocyte-intrinsic tumorigenic signaling from these oncoproteins, even if Shp2 deficiency induces a tumor-promoting hepatic microenvironment. These data suggest a new and more effective therapeutic strategy for HCCs driven by oncogenic RTKs and other upstream molecules, by inhibiting Shp2 and also suppressing any tumor-enhancing stromal factors produced because of Shp2 inhibition. LAY SUMMARY: Primary liver cancer is a malignant disease with poor prognosis, largely because there are limited systemic therapies available. We show here that a cytoplasmic tyrosine phosphatase Shp2 is required for liver tumorigenesis. This tumorigenesis is driven by two oncoproteins that are implicated in human liver cancer. This, together with our previous studies, uncovers the complexity of liver tumorigenesis, by elucidating the pro- and anti-tumor effects of Shp2 in mouse models. This data can be used to guide new therapies.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Liu JJ, Li Y, Chen WS, et al. Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET. J Hepatol. 2018. PMID: 29505847. doi:10.1016/j.jhep.2018.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。